American Century Companies’s Maze Therapeutics MAZE Stock Holding History

American Century Companies’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,635	Closed	-$288K	–	3019
2026 Q1	$288K	Sell	9,635 -11,874	-55%	-$524K	﹤0.01%	2648
2025 Q4	$891K	Buy	+21,509	New	+$739K	﹤0.01%	2354

Other funds holding MAZE

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

American Century Companies's MAZE Position: Q2 2026 in Review

American Century Companies sold out of Maze Therapeutics (MAZE) in Q2 2026, closing a stake of 9,635 shares — an estimated $288K sold.

American Century Companies first reported a position in MAZE in Q4 2025 and held it in 2 quarters. The position peaked at $891K in Q4 2025. 151 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

American Century Companies reported no remaining Maze Therapeutics position as of Q2 2026 after selling out during the quarter.
American Century Companies sold 9,635 Maze Therapeutics shares in Q2 2026, an estimated $288K.
American Century Companies first reported a position in Maze Therapeutics in Q4 2025 and held it in 2 quarters.
American Century Companies's Maze Therapeutics position peaked at $891K in Q4 2025.
151 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.